Potential therapeutic target for colon cancer
- Date:
- May 7, 2010
- Source:
- World Journal of Gastroenterology
- Summary:
- A research team from China investigated the association between peroxisome proliferator-activated receptor-gamma (PPAR-gamma) gene polymorphism 34 C>G and colorectal cancer (CRC) through a meta-analysis. They found PPAR-gamma 34 C>G is associated with colon cancer risk, but not associated with CRC and rectal cancer risk.
- Share:
Colorectal cancer (CRC) is one of the major causes of cancer death in the developed countries. Accumulated evidences indicate that lipid metabolism, especially the one in the arachidonic acid (AA)-pathway, appears to play a critical role in the development of CRC.
The peroxisome proliferator-activated receptor-γ (PPAR-γ) gene, one of the most important components of the AA-pathway, has been verified to express in a variety of tumor cells. Many studies have been performed about the association between the polymorphism 34 C>G of PPAR-γgene and CRC, but got conflicting results.
A research article to be published on May 7, 2010 in the World Journal of Gastroenterology addresses this question. A research team led by Professor Li-Cheng Dai, confirmed the former data of the association between PPAR-γgene 34 C>G and CRC in the meta-analysis.
In this report, the association between PPAR-γ gene polymorphism 34 C>G and colon cancer risk was observed, and the G allele decreased the colon cancer risk, which is meaningful to early diagnosis, prevention and individual-based treatment of colon cancer. Furthermore, 34 C>G of PPAR-γ gene might be a potential therapeutic target for colon cancer.
Story Source:
Materials provided by World Journal of Gastroenterology. Note: Content may be edited for style and length.
Journal Reference:
- Lu YL, Li GL, Huang HL, Zhong J, Dai LC. Peroxisome proliferator-activated receptor-γ 34C>G polymorphism and colorectal cancer risk: A meta-analysis. World J Gastroenterol, 2010; 16 (17): 2170-2175 DOI: 10.3748/wjg.v16.i17.2170
Cite This Page: